Background: Preoperative single high-dose glucocorticoid may have early outcome benefits in total hip arthroplasty (THA) and knee arthroplasty (TKA), but long-term safety aspects have not been evaluated. Methods: From October 2013, the departments reporting to the prospective Lundbeck Foundation Database for Fast-track Hip and Knee Replacement introduced preoperative methylprednisolone (MP) 125 mg as part of a multimodal analgesic protocol in TKA. We analysed the risk of length of hospital stay (LOS) >4 days, 30 and 90 day readmissions in patients with MP vs patients having TKA before the use of MP and adjusted for comorbidity and place of surgery. An unadjusted comparison was specifically done to evaluate deep prosthetic infections. Results: Of a total of 3927 TKA procedures, 1442 received MP. Median LOS was 2 days in both groups, but the fraction with LOS >4 days was 6.0% vs 11.5% (P<0.001) in patients with MP vs those without, and with a reduced risk of LOS >4 days in adjusted analysis [odds ratio (OR) 0.51; confidence interval (CI) 0.39-0.68; P<0.001]. Readmission rates were 5.6% (CI 4.5-6.9) vs 4.4% (P¼0.095) and 7.8% vs 7.3% (P¼0.53) at 30 and 90 days with and without MP, respectively. Adjusted analysis did not identify MP to be associated with 30 day (OR 1.18; CI 0.89-1.56; P¼0.25) or 90 day (OR 1.12; CI 0.86-1.46; P¼0.39) readmissions. The incidence of deep infections requiring surgical intervention was 0.8% vs 0.7% with MP vs without, respectively (P¼0.78). Conclusions: In this detailed prospective cohort study, preoperative high-dose glucocorticoid administration was not associated with LOS >4 days, readmissions or infectious complications in TKA patients without contraindications. Clinical trial registration: NCT01515670.
prophylaxis. [3] [4] [5] Thus, some recent studies in major joint arthroplasty have found significant benefits on pain, even when combined with basic evidence-based multimodal analgesia. [6] [7] [8] [9] In addition, preoperative administration of such 'high dose' glucocorticoids in other major procedures is promising to enhance recovery by reducing the surgery induced inflammatory response. [10] [11] [12] However, despite these early promising effects, clinicians have been reluctant to use high doses of preoperative glucocorticoids because of a relevant concern about side-effects on wound healing and risk of infections, although existing data from other procedures have not demonstrated any safety issues to date. 4 6-9 13-15 Furthermore, because of their effect on gene transcription, glucocorticoids have numerous potential systemic side-effects, including neuropsychiatric and cardiovascular problems, disturbances in glucose balance and increased risk of gastric ulcers, especially when combined with non-steroidal anti-inflammatory drugs. 16 17 Although most side-effects of steroids occur with long-term treatment, a study in patients with multiple sclerosis receiving pulse therapy for attacks found that patient-reported adverse effects occurred on the second day in >50% of patients, 18 and the onset of neuropsychiatric symptoms may also occur after as little as five days of treatment with 40 mg of prednisone. 19 However, in this context, the effect of a single high-dose glucocorticoid in surgical patients is unknown. 13 Based on the documented positive analgesic effect and early positive outcome results of high-dose glucocorticoids in major joint arthroplasty, [6] [7] [8] several centres from the Lundbeck Foundation collaboration for Fast-track Hip and Knee arthroplasty decided to introduce routine use of high-dose glucocorticoid in TKA beginning in October 2013. At the same time, a study protocol was designed in order to provide one year safety data regarding prosthetic infections in a large prospective cohort compared with the previous prospective cohort that did not receive preoperative glucocorticoid. However, in order to provide data about other potential glucocorticoid-related safety issues in the early 90 day postoperative phase, a separate analysis on associations with prolonged length of hospital stay (LOS) and 90 day readmissions was also planned.
Methods
This study was based on the ongoing prospective study registry on patient characteristics administered by the Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaboration (www.fthk.dk), 20 which is registered on ClinicalTrials.gov (NCT01515670). Parts of the study cohort have been reported previously in different works focusing on preoperative risk factors and postoperative morbidity. 21 22 Prior to the surgical procedure, all patients having THA and TKA in the participating departments complete a questionnaire on comorbidity and other demographic information, which is subsequently merged with the Danish National Database on Reimbursed Prescriptions for additional information on dispensed drugs before and after surgery. 23 Follow-up on LOS (defined as nights spent in hospital), 90 day readmissions requiring overnight stay in hospital and mortality is acquired through the Danish National Patient Registry (DNPR). As reporting to the DNPR is required to receive reimbursement from the Danish government, complete follow-up is assured. 24 Finally, any case of LOS >4 days, readmissions or mortality is followed by the review of discharge papers and, if necessary, the complete medical records, in order to determine the type of morbidity. These are then divided into 'medical' and 'surgical' complications based on previous works 22 (Table 1) . From
October 2013 to October 2015, the centres at different time periods decided to use methylprednisolone (MP) 125 mg preoperatively. Information on whether each patient had received MP as well as reasons for not giving it were prospectively reported in all elective TKA patients. The initial contraindications for MP were standardized and included: allergy to glucocorticoids; preoperative systemic glucocorticoid treatment; insulin-dependent diabetes mellitus (IDDM); and active gastric ulcer. At the same time, a study protocol for providing one year safety data specifically on prosthetic infections was designed and registered at ClinicalTrials.gov (NCT02019511). No other major changes to the implemented fast-track protocols were reported during the study period. In this separate analysis on postoperative morbidity, resulting in a LOS >4 days or readmissions/mortality within 90 days of surgery, consecutive data were included from January 2012 to October 2014, and only in those centres who had initiated high-dose glucocorticoids within this time period. Patients reported to have IDDM prescriptions for insulin or systemic glucocorticoids within 90 days pre-or postoperatively were excluded from the control group, which had all had surgery between January 2012 and to the start of using MP.
Ethics
No approval from the National Ethics Committee was necessary as this was a non-interventional observational study. Permission to store and review patient data was given by the Danish National Board of Health (j. 
Outcomes
The primary outcomes were to investigate associations between MP and LOS >4 days and 90 day readmissions. Secondary outcomes were 30 day readmissions and associations between MP and 'medical' or 'surgical' complications leading to LOS >4 days or 30 or 90 day readmissions. Finally, as prosthetic infection remains a major concern in TKA, a specific analysis was conducted for the potential increased risk of deep prosthetic infection within 90 days of surgery.
Results
Of a total of 4363 performed TKAs during the study period, 3927 (90.0%) procedures were available for final analysis ( Fig. 1 ). Of these, 1442 (37%) had received MP (MP patients) and 2485 (63%) had not (controls). There were more patients with preoperative cardiac and pulmonary disease as well as anticoagulant users among MP patients than controls, while more controls lived alone, had a psychiatric disorder or NIDDM (Table 2) . Median LOS was 2 days (IQR 2-3) in both groups; however, the fraction of patients with a LOS >4 days was 6.0% (CI 5.9-7.4) in MP patients vs 11.5% (CI 10. .117], respectively. All-cause 90 day mortality was 0.1% in both groups of which one patient died of a cardiac arrest on postoperative day 29 (MP patient), two patients died of unknown reasons (postoperative days 61 and 88, both controls) and one patient due to worsening of chronic pulmonary fibrosis (postoperative day 58, control). Due to missing covariates, 238 (6%) patients were excluded from the adjusted analysis, of which 96 were MP patients (7% of MP patients) and 142 were controls (6% of controls). A LOS >4 days occurred in four (4.3%) MP patients and in 15 (10.6%) controls. Readmissions at 30 days occurred in four (4.3%) MP patients and in seven (4.9%) controls, increasing to seven (7.6%) and 10 (7.0%) at 90 days postoperatively.
In the remaining 3689 (94%) patients, the adjusted analysis found MP to be associated with a reduced risk of LOS >4 days (OR 0.51; CI 0.39-0.68; P<0.001). This was significant for 'medical' (OR 0.47; CI 0.32-0.68; P<0.001) but not 'surgical' (OR 0.89; CI 0.61-1.32; P¼0.572) causes of LOS >4 days (Table 4 ). There was no significant association between MP and 30 (OR 1.18; CI 0.89-1.56; P¼0.248) or 90 day readmissions (OR 1.12; CI 0.86-1.46; P¼0.389) alone (Table 5) . Neither was there any significant association with 90 days 'medical' (OR 1.13; CI 0.83-1.52; P¼0.439) nor 'surgical' readmissions (OR 1.05; CI 0.75-1.47; P¼0.790) ( Table 5) . A total of 28 (0.7%, CI 0.5-1.0) deep prosthetic infections requiring return to surgery occurred, of which 11 (0.8%, CI 0.4-1.4) were in MP patients and 17 (0.7%, CI 0.4-1.1; P¼0.777) in controls. No adjusted analysis was performed on the risk of prosthetic infection as there were too few events for meaningful analysis.
Patients excluded from main analysis
Of the total 266 (16%) TKA patients who had not received MP, 47 (3%) were because of IDDM, 33 (2%) because of preoperative glucocorticoid treatment and 27 (2%) because of gastric ulcer (Fig. 1) . Median LOS was 3 days (IQR 2-4), 13.9% (CI 10.3-18.6) had a LOS >4 days, and 30 and 90 day readmission rates were 6.8% (CI 4.3-10.5) and 10.2% (CI 7.1-14.4), respectively. There was one death (0.4%) due to myocardial infarction on day 2 postoperative. There were two (0.8%, CI 0.2-2.7) patients who were readmitted with superficial infections treated with antibiotics only.
Of the 170 (7%) patients who were excluded from the control group, 94 (4%) were because of dispensed prescriptions for systemic glucocorticoids and 76 (3%) were because of reported type 1 diabetes or dispensed prescriptions for insulin (Fig. 1) . Median LOS was 3 days (IQR 2-4), 16.5% (CI 11.7-22.8) had LOS >4 days, and 30 and 90 day readmission rates were 10.6% (CI 6.8-16.1) and 12.9% (CI 8.7-18.8), respectively. There were three patients who were readmitted because of infections (1.8%, CI 0.6-5.1), of which two were superficial and treated by wound sanitation or antibiotics only and one (0.6%, CI 0.1-3.3) had a deep prosthetic infection and died of respiratory distress after several revision procedures followed by amputation 82 days postoperatively.
Sensitivity and post hoc power analysis
The sensitivity analysis found that our study was powered to find a minimal OR of 1.9 for 30 day and 1.7 for 90 day readmissions when using an a of 0.05, a b of 0.80 and a R 2 value of the other variables of 0.90. Furthermore, for our results on LOS >4 days to become statistically insignificant, an unmeasured confounder with an OR of 0.5 would have to be present in about 70% of the patients who received MP and absent from all controls. Also, an unmeasured confounder would not be able to make MP associated with increased risk of LOS >4 days (Supplementary Table S1 ). In contrast, an unmeasured confounder would need to be present in about 30% of MP patients and none of the controls to hide a significantly increased OR for 30 day (OR 1. Tables S2 and S3 ). Finally, a post hoc power analysis on the results of the adjusted analysis of LOS >4 days found that with an a of 0.05 and a R 2 value of the other variables of 0.90, our study power was 0.97.
Discussion
Preoperative administration of small doses of glucocorticoid (dexamethasone 4-8 mg) is well established for PONV prophylaxis and is unlikely to have significant side-effects, 3-5 26 despite a small and probably insignificant observed increase in blood glucose, including in diabetic patients. 4 27 More recently, there has been interest in using higher doses of glucocorticoids preoperatively because of their anti-inflammatory and analgesic effects [6] [7] [8] [9] [10] [11] [12] as several inflammatory responses to surgery may have undesirable effects on organ function and risk of complications. 28 Although positive effects of high-dose glucocorticoid on early recovery in THA and TKA have been demonstrated, 6 8 9 relevant concerns about side-effects are unresolved in these operations because of the underpowered pre-existing small randomized trials. 13 However, previous trials in other types of surgery, 4 including high-risk pancreaticoduodenectomy 29 and ) had no effect on wound healing assessed by collagen synthesis in subcutaneously implanted tubes. 15 Our non-randomized but consecutive comparative cohort study in a large group of TKA patients could not demonstrate any increased risks of preoperative MP 125 mg on neither medical nor direct surgical complications, including deep infections. In contrast, although it was not the aim of the present study, the positive effects on pain and early fatigue demonstrated in previous randomized controlled trials 6 8 9 may be indirectly supported by the demonstrated reduced risk of LOS >4 days. However, despite being the largest observational study with 1442 glucocorticoid-treated patients vs 2485 controls, there is an obvious need for larger series or direct randomized controlled trials, in order to identify whether specific types of complications may be reduced when using preoperative high-dose MP in TKA. Nonetheless, as pain management after THA and TKA is still controversial and unsolved, especially in TKA, 12 the present safety data indicate that future dose-finding studies as well as repeat-dosing studies do not compromise patient safety. Study limitations include the use of a historical cohort, which potentially may have included more patients with various comorbidities despite not being direct contraindications which we have accounted for. For example, although NIDDM was not a contraindication for MP, we found that a considerable number of patients allegedly did not receive MP because of NIDDM. However, NIDDM has not been found to have an influence on LOS >4 days or readmissions in fast-track THA and TKA, 21 and our study design did enable us to exclude patients with IDDM in both groups, which may be more important. 21 Furthermore, our study depended on the review of discharge records, and the quality of these may potentially have influenced the categorization of 'medical' and 'surgical' causes of morbidity. Nonetheless, we believe such an approach to be preferable to using diagnostic codes, which often are of uncertain validity. 32 Regarding our logistic regression analysis, we were only able to include the covariates from our prospective questionnaire, while other important potential confounders such as blood loss or detailed information on peripheral vascular disease were unavailable. Our analysis on the influence of a hypothetical potential unmeasured confounder with an OR of 0.5 found that the effect on LOS >4 days was limited, it could influence our results regarding readmissions. It could be suggested that our findings of a lack of association between MP and increased LOS or readmissions was because of other improvements in perioperative care during the time period biasing our results. However, the participating departments have all had well-established fast-track protocols for several years and the fraction with LOS >4 days or 90 day readmissions from 2012 to 2014 in the patients who did not receive MP remained stationary. Thus, it seems unlikely that changes in perioperative care between 2012 and 2014 would affect LOS or readmission rates to such a degree that it would hide potential increase associated with MP. Our sensitivity analysis on readmissions may suggest that the sample size was too small, and consequently, further studies are needed to confirm that MP is not associated with an increase in readmissions. However, based on our results, such a study would need to include about 90 000 patients. The strengths of our study are larger patient groups than previously available, the detailed preoperative co-morbidity assessment and the complete 90 days follow-up through the nationwide Danish registry (DNPR) and discharge records. The use of the DNPR also allowed us to exclude those controls who had dispensed prescriptions for glucocorticoids preoperatively, which may be of importance as this is often used in patients with rheumatoid arthritis, which in itself is a risk factor for worse postoperative outcomes, 33 including deep infections. 34 Finally, our use of multiple logistic regression analysis should have limited the effect of other comorbidity imbalances.
In conclusion, this large-scale, comparative non-randomized cohort study in elective primary TKA patients with detailed 90 days follow-up did not demonstrate any safety issues regarding the risk of a LOS >4 days or readmissions with preoperative administration of MP 125 mg. As a result of previously demonstrated positive recovery effects of preoperative MP, the results should stimulate future dose-finding, repeat-dosing and safety studies.
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